☆ 4.7 Article

Baseline serum neurofilament light chain levels differentiate aggressive from benign forms of relapsing-remitting multiple sclerosis: a 20-year follow-up cohort

JOURNAL OF NEUROLOGY (2023)

Related references

Note: Only part of the references are listed.

Article Clinical Neurology

Serum NfL but not GFAP predicts cognitive decline in active progressive multiple sclerosis patients

Christian Barro et al.

Summary: This study suggests that serum neurofilament light chain (sNfL) levels are associated with cognitive decline in multiple sclerosis (MS) patients and can predict cognitive impairment, especially in active patients. However, serum glial fibrillary acidic protein (sGFAP) is not associated with cognitive function.

MULTIPLE SCLEROSIS JOURNAL (2023)

Add to Collection

Article Clinical Neurology

Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis

Stephanie Meier et al.

Summary: This study found that serum glial fibrillary acidic protein (sGFAP) and serum neurofilament light chain (sNfL) are correlated with features of disease progression in multiple sclerosis (MS) and can predict disease progression. sGFAP may serve as a useful biomarker for disease progression in MS in individual patient management and drug development.

JAMA NEUROLOGY (2023)

Add to Collection

Article Clinical Neurology

Serum GFAP and NfL Levels Differentiate Subsequent Progression and Disease Activity in Patients With Progressive Multiple Sclerosis

Christian Barro et al.

Summary: Neurodegeneration and astrocytic activation are characteristic pathological features of progressive MS. sNfL and sGFAP can be used as tools to stratify patients based on progression and disease activity status.

NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2023)

Add to Collection

Article Clinical Neurology

Glial fibrillary acidic protein and multiple sclerosis progression independent of acute inflammation

Xiaotong Jiang et al.

Summary: This study analyzed the association between serum glial fibrillary acidic protein (sGFAP) concentration and disability progression in patients with secondary-progressive multiple sclerosis (SPMS). The results showed that changes in sGFAP concentration were not associated with current disability progression and could not predict future disability progression in the absence of inflammatory activity.

MULTIPLE SCLEROSIS JOURNAL (2023)

Add to Collection

Article Clinical Neurology

Association of Serum Neurofilament Light Chain Levels at Disease Onset With Disability Worsening in Patients With a First Demyelinating Multiple Sclerosis Event Not Treated With High-Efficacy Drugs

Enric Monreal et al.

Summary: This multicenter cohort study found that high serum neurofilament light chain (sNfL) values obtained within the first year of disease were associated with long-term disability worsening in patients with multiple sclerosis (MS), suggesting that sNfL level measurement may help identify optimal candidates for highly effective disease-modifying treatments.

JAMA NEUROLOGY (2023)

Add to Collection

Article Clinical Neurology

Early neurofilament light and glial fibrillary acidic protein levels improve predictive models of multiple sclerosis outcomes

Gauruv Bose et al.

Summary: Current predictive models based on clinical and imaging characteristics can help with early risk-stratification in multiple sclerosis. Serum biomarkers, such as sNfL and sGFAP, provide additional information about subclinical disease activity and can improve the accuracy of predictive models for clinical and MRI outcomes.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2023)

Add to Collection

Article Immunology

Kappa free light chains index in multiple sclerosis very long-term prognosis

Pablo Arroyo-Pereiro et al.

Summary: The potential of kappa-free light chain (kFLC) as a long-term prognostic marker for multiple sclerosis (MS) was explored in this study. The results showed no significant differences in kFLC index between the two groups with different disease courses, indicating that kFLC is unlikely to be a reliable marker for long-term prognosis in MS.

FRONTIERS IN IMMUNOLOGY (2023)

Add to Collection

Review Clinical Neurology

Blood GFAP as an emerging biomarker in brain and spinal cord disorders

Ahmed Abdelhak et al.

Summary: Blood-derived biomarkers, such as glial fibrillary acidic protein (GFAP), hold promise in the diagnosis and prognosis of neurological diseases. However, there are limitations that hinder the widespread clinical use of GFAP as a biomarker.

NATURE REVIEWS NEUROLOGY (2022)

Add to Collection

Article Clinical Neurology

Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study

Pascal Benkert et al.

Summary: sNfL is a biomarker of neuronal damage used in monitoring disease activity in multiple sclerosis patients. This study established a reference database to correct for age and BMI, showing sNfL's potential in identifying individuals at risk for future disease activity. The results suggest that sNfL Z scores could predict acute and chronic disease activity in multiple sclerosis patients, with higher Z scores indicating increased risk.

LANCET NEUROLOGY (2022)

Add to Collection

Article Clinical Neurology

Plasma glial fibrillary acidic protein and neurofilament light chain in relation to disability worsening in multiple sclerosis

Ayla Pauwels et al.

Summary: In multiple sclerosis, plasma NfL is associated with long-term sustained disability worsening, while plasma GFAP is not.

MULTIPLE SCLEROSIS JOURNAL (2022)

Add to Collection

Article Clinical Neurology

Baseline neurofilament levels in cerebrospinal fluid do not correlate with long-term prognosis in multiple sclerosis

Athina-Maria Aloizou et al.

Summary: This study explored the potential of neurofilament light-chain (NfL) as a prognostic marker in multiple sclerosis (MS). By measuring NfL levels in cerebrospinal fluid and conducting long-term follow-up, the authors found no significant association between NfL levels and age, disability, or severity. However, there was a significant association between older age of onset and disability and severity.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2022)

Add to Collection

Article Clinical Neurology

Serum neurofilament light chain reflects inflammation-driven neurodegeneration and predicts delayed brain volume loss in early stage of multiple sclerosis

Barbora Srpova et al.

Summary: The study found a strong relationship between sNfL level changes and lesion burden accumulation in MS, but not with brain volume loss. Early sNfL levels were predictive of future brain volume loss. Patients with NEDA-3 status had lower sNfL levels compared to active MS patients.

MULTIPLE SCLEROSIS JOURNAL (2021)

Add to Collection

Article Clinical Neurology

Temporal profile of serum neurofilament light in multiple sclerosis: Implications for patient monitoring

Peter A. Calabresi et al.

Summary: The study aimed to explore the use of sNfL as a prognostic biomarker in MS, and results showed that sNfL could predict brain volume change and development of new T2 lesions over 4 years. Patients treated with peginterferon beta-1a showed significant improvements in clinical and MRI outcomes when sNfL levels decreased. sNfL levels were higher and more variable in patients with evidence of active MS.

MULTIPLE SCLEROSIS JOURNAL (2021)

Add to Collection

Article Clinical Neurology

Plasma Tau and Neurofilament Light in Frontotemporal Lobar Degeneration and Alzheimer Disease

Ignacio Illan-Gaia et al.

Summary: Plasma NfL outperforms plasma t-tau in distinguishing between FTLD-S and AD-S, predicting clinical decline and survival, and correlating with regional cortical thickness; while plasma t-tau shows inferior performance in these aspects.

NEUROLOGY (2021)

Add to Collection

Review Clinical Neurology

Chitinases and chitinase-like proteins as biomarkers in neurologic disorders

Rucsanda Pinteac et al.

Summary: Chitinases are hydrolytic enzymes widely distributed in nature and are emerging as biomarkers in neurologic disorders. This review summarizes the structural features of human chitinases and their potential roles in the CNS, as well as the evidence for their use as diagnostic and prognostic biomarkers in inflammatory, neurodegenerative diseases, and psychiatric disorders. Future perspectives of chitinase studies in neurologic conditions are also discussed.

NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2021)

Add to Collection

Article Clinical Neurology

Cerebrospinal Tau levels as a predictor of early disability in multiple sclerosis

Eleonora Virgilio et al.

Summary: CSF Tau levels may predict early disability accumulation in Multiple Sclerosis patients. Other predictors of disability include spinal cord involvement, age at MS diagnosis, and high brain lesion load.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2021)

Add to Collection

Article Clinical Neurology

A novel prognostic score to assess the risk of progression in relapsing-remitting multiple sclerosis patients

Anna Isabella Pisani et al.

Summary: By using machine learning methods in RRMS patients, predictive factors associated with the risk of converting to SPMS were identified, leading to the development of the SP-RiSc score, which can help improve management strategies.

EUROPEAN JOURNAL OF NEUROLOGY (2021)

Add to Collection

Article Clinical Neurology

Scoring the 10-year risk of ambulatory disability in multiple sclerosis: the RoAD score

Claudio Gasperini et al.

Summary: The study aimed to develop and validate a scoring system combining baseline prognostic factors and 1-year variables of treatment response to predict the long-term risk of disability accumulation in patients with RRMS. The RoAD score showed to be a useful tool in predicting the risk of reaching a disability milestone and optimizing treatment strategy for RRMS patients.

EUROPEAN JOURNAL OF NEUROLOGY (2021)

Add to Collection

Article Clinical Neurology

Infratentorial and spinal cord lesions: Cumulative predictors of long-term disability?

Iris Dekker et al.

MULTIPLE SCLEROSIS JOURNAL (2020)

Add to Collection

Article Clinical Neurology

The long-term outcomes of CIS patients in the Barcelona inception cohort: Looking back to recognize aggressive MS

Mar Tintore et al.

MULTIPLE SCLEROSIS JOURNAL (2020)

Add to Collection

Article Clinical Neurology

Serum glial fibrillary acidic protein correlates with multiple sclerosis disease severity

Heidi Hogel et al.

MULTIPLE SCLEROSIS JOURNAL (2020)

Add to Collection

Article Clinical Neurology

Blood neurofilament light levels segregate treatment effects in multiple sclerosis

Benedicte Delcoigne et al.

NEUROLOGY (2020)

Add to Collection

Article Clinical Neurology

Early clinical markers of aggressive multiple sclerosis

Charles B. Malpas et al.

BRAIN (2020)

Add to Collection

Article Clinical Neurology

Plasma neurofilament light levels are associated with risk of disability in multiple sclerosis

Ali Manouchehrinia et al.

NEUROLOGY (2020)

Add to Collection

Article Clinical Neurology

CSF chitinase 3-like-1 association with disability of primary progressive MS

Francisco Perez-Miralles et al.

NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2020)

Add to Collection

Review Clinical Neurology

Aggressive multiple sclerosis (1): Towards a definition of the phenotype

Ellen Iacobaeus et al.

MULTIPLE SCLEROSIS JOURNAL (2020)

Add to Collection

Review Clinical Neurology

Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis

Daniel Ontaneda et al.

LANCET NEUROLOGY (2019)

Add to Collection

Article Clinical Neurology

Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD

Mitsuru Watanabe et al.

NEUROLOGY (2019)

Add to Collection

Article Multidisciplinary Sciences

Chi3l3 induces oligodendrogenesis in an experimental model of autoimmune neuroinflammation

Sarah C. Starossom et al.

NATURE COMMUNICATIONS (2019)

Add to Collection

Article Clinical Neurology

Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria

Alan J. Thompson et al.

LANCET NEUROLOGY (2018)

Add to Collection

Review Medicine, General & Internal

Multiple Sclerosis

Daniel S. Reich et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Article Clinical Neurology

Serum neurofilament is associated with progression of brain atrophy and disability in early MS

Jens Kuhle et al.

NEUROLOGY (2017)

Add to Collection

Article Clinical Neurology

Predictors of Long-Term Disability Accrual in Relapse-Onset Multiple Sclerosis

Vilija G. Jokubaitis et al.

ANNALS OF NEUROLOGY (2016)

Add to Collection

Review Clinical Neurology

Precision medicine in multiple sclerosis: biomarkers for diagnosis, prognosis, and treatment response

Manuel Comabella et al.

CURRENT OPINION IN NEUROLOGY (2016)

Add to Collection

Article Immunology

Glial and neuronal markers in cerebrospinal fluid in different types of multiple sclerosis

M. Alba Mane-Martinez et al.

JOURNAL OF NEUROIMMUNOLOGY (2016)

Add to Collection

Letter Computer Science, Information Systems

Youden's Index and the Weight of Evidence Revisited

G. Hughes

METHODS OF INFORMATION IN MEDICINE (2015)

Add to Collection

Article Clinical Neurology

Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis

M. Alba Mane Martinez et al.

MULTIPLE SCLEROSIS JOURNAL (2015)

Add to Collection

Article Clinical Neurology

Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis

M. Alba Mane Martinez et al.

MULTIPLE SCLEROSIS JOURNAL (2015)

Add to Collection

Article Clinical Neurology

Scoring treatment response in patients with relapsing multiple sclerosis

M. P. Sormani et al.

MULTIPLE SCLEROSIS JOURNAL (2013)

Add to Collection

Article Clinical Neurology

Chitinase 3-like 1 plasma levels are increased in patients with progressive forms of multiple sclerosis

E. Canto et al.

MULTIPLE SCLEROSIS JOURNAL (2012)

Add to Collection

Article Clinical Neurology

Benign multiple sclerosis: a need for a consensus

S. B. Glad et al.

ACTA NEUROLOGICA SCANDINAVICA (2010)

Add to Collection

Review Geriatrics & Gerontology

Total and phosphorylated tau protein as biological markers of Alzheimer's disease

Harald Hampel et al.

EXPERIMENTAL GERONTOLOGY (2010)

Add to Collection

Article Immunology

In vivo CHI3L1 (YKL-40) expression in astrocytes in acute and chronic neurological diseases

Dafna Bonneh-Barkay et al.

JOURNAL OF NEUROINFLAMMATION (2010)

Add to Collection

Article Clinical Neurology

Early MRI in optic neuritis The risk for disability

J. K. Swanton et al.

NEUROLOGY (2009)

Add to Collection

Article Clinical Neurology

Disability and T2 MRI lesions:: a 20-year follow-up of patients with relapse onset of multiple sclerosis

L. K. Fisniku et al.

BRAIN (2008)

Add to Collection

Article Clinical Neurology

Cerebrospinal fluid total tau protein levels in patients with multiple sclerosis

M. Terzi et al.

ACTA NEUROLOGICA SCANDINAVICA (2007)

Add to Collection

Article Clinical Neurology

Infratentorial lesions predict long-term disability in patients with initial findings suggestive of multiple sclerosis

A Minneboo et al.

ARCHIVES OF NEUROLOGY (2004)

Add to Collection

Article Clinical Neurology

Neurofilament and glial fibrillary acidic protein in multiple sclerosis

N Norgren et al.

NEUROLOGY (2004)

Add to Collection

Article Neurosciences

Tau protein in cerebrospinal fluid:: a possible marker of poor outcome in patients with early relapsing-remitting multiple sclerosis

A Martínez-Yélamos et al.

NEUROSCIENCE LETTERS (2004)

Add to Collection

Article Mathematical & Computational Biology

A non-parametric method for the comparison of partial areas under ROC curves and its application to large health care data sets

DD Zhang et al.

STATISTICS IN MEDICINE (2002)

Add to Collection

Review Biochemistry & Molecular Biology

Glial fibrillary acidic protein: GFAP-thirty-one years (1969-2000)

LF Eng et al.

NEUROCHEMICAL RESEARCH (2000)

Add to Collection

© Peeref 2019-2024. All rights reserved.